These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 21474353)

  • 1. A safety trial of high dose glyceryl triacetate for Canavan disease.
    Segel R; Anikster Y; Zevin S; Steinberg A; Gahl WA; Fisher D; Staretz-Chacham O; Zimran A; Altarescu G
    Mol Genet Metab; 2011 Jul; 103(3):203-6. PubMed ID: 21474353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress toward acetate supplementation therapy for Canavan disease: glyceryl triacetate administration increases acetate, but not N-acetylaspartate, levels in brain.
    Mathew R; Arun P; Madhavarao CN; Moffett JR; Namboodiri MA
    J Pharmacol Exp Ther; 2005 Oct; 315(1):297-303. PubMed ID: 16002461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glyceryl triacetate for Canavan disease: a low-dose trial in infants and evaluation of a higher dose for toxicity in the tremor rat model.
    Madhavarao CN; Arun P; Anikster Y; Mog SR; Staretz-Chacham O; Moffett JR; Grunberg NE; Gahl WA; Namboodiri AMA
    J Inherit Metab Dis; 2009 Oct; 32(5):640. PubMed ID: 19685155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic acetate therapy improves phenotype in the tremor rat model of Canavan disease.
    Arun P; Madhavarao CN; Moffett JR; Hamilton K; Grunberg NE; Ariyannur PS; Gahl WA; Anikster Y; Mog S; Hallows WC; Denu JM; Namboodiri AM
    J Inherit Metab Dis; 2010 Jun; 33(3):195-210. PubMed ID: 20464498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Canavan disease and the role of N-acetylaspartate in myelin synthesis.
    Namboodiri AM; Peethambaran A; Mathew R; Sambhu PA; Hershfield J; Moffett JR; Madhavarao CN
    Mol Cell Endocrinol; 2006 Jun; 252(1-2):216-23. PubMed ID: 16647192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triacetin-based acetate supplementation as a chemotherapeutic adjuvant therapy in glioma.
    Tsen AR; Long PM; Driscoll HE; Davies MT; Teasdale BA; Penar PL; Pendlebury WW; Spees JL; Lawler SE; Viapiano MS; Jaworski DM
    Int J Cancer; 2014 Mar; 134(6):1300-10. PubMed ID: 23996800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-Acetylaspartate Synthase Deficiency Corrects the Myelin Phenotype in a Canavan Disease Mouse Model But Does Not Affect Survival Time.
    Maier H; Wang-Eckhardt L; Hartmann D; Gieselmann V; Eckhardt M
    J Neurosci; 2015 Oct; 35(43):14501-16. PubMed ID: 26511242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A mutation of aspartoacylase gene in a Turkish patient with Canavan disease.
    Eke GH; Iscan A; Cece H; Calik M
    Genet Couns; 2012; 23(1):9-12. PubMed ID: 22611636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New T530C mutation in the aspartoacylase gene caused Canavan disease with no correlation between severity and N-acetylaspartate excretion.
    Di Pietro V; Cavallari U; Amorini AM; Lazzarino G; Longo S; Poggiani C; Cavalli P; Tavazzi B
    Clin Biochem; 2013 Dec; 46(18):1902-4. PubMed ID: 24036223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic acetate therapy for the treatment of traumatic brain injury.
    Arun P; Ariyannur PS; Moffett JR; Xing G; Hamilton K; Grunberg NE; Ives JA; Namboodiri AM
    J Neurotrauma; 2010 Jan; 27(1):293-8. PubMed ID: 19803785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Knock-out mouse for Canavan disease: a model for gene transfer to the central nervous system.
    Matalon R; Rady PL; Platt KA; Skinner HB; Quast MJ; Campbell GA; Matalon K; Ceci JD; Tyring SK; Nehls M; Surendran S; Wei J; Ezell EL; Szucs S
    J Gene Med; 2000; 2(3):165-75. PubMed ID: 10894262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acetate supplementation as a means of inducing glioblastoma stem-like cell growth arrest.
    Long PM; Tighe SW; Driscoll HE; Fortner KA; Viapiano MS; Jaworski DM
    J Cell Physiol; 2015 Aug; 230(8):1929-43. PubMed ID: 25573156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical clinical and radiological course of a patient with Canavan disease.
    Sarret C; Boespflug-Tanguy O; Rodriguez D
    Metab Brain Dis; 2016 Apr; 31(2):475-9. PubMed ID: 26586007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of topiramate on enlargement of head in Canavan disease: a new option for treatment of megalencephaly.
    Topçu M; Yalnizoğlu D; Saatçi I; Haliloğlu G; Topaloğlu H; Senbil N; Onol S; Coşkun T
    Turk J Pediatr; 2004; 46(1):67-71. PubMed ID: 15074377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Canavan disease: clinical features and recent advances in research.
    Hoshino H; Kubota M
    Pediatr Int; 2014 Aug; 56(4):477-83. PubMed ID: 24977939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Canavan disease: a white matter disorder.
    Kumar S; Mattan NS; de Vellis J
    Ment Retard Dev Disabil Res Rev; 2006; 12(2):157-65. PubMed ID: 16807907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Restoration of aspartoacylase activity in CNS neurons does not ameliorate motor deficits and demyelination in a model of Canavan disease.
    Klugmann M; Leichtlein CB; Symes CW; Serikawa T; Young D; During MJ
    Mol Ther; 2005 May; 11(5):745-53. PubMed ID: 15851013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defective N-acetylaspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan's disease.
    Madhavarao CN; Arun P; Moffett JR; Szucs S; Surendran S; Matalon R; Garbern J; Hristova D; Johnson A; Jiang W; Namboodiri MA
    Proc Natl Acad Sci U S A; 2005 Apr; 102(14):5221-6. PubMed ID: 15784740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lithium citrate as treatment of Canavan disease.
    Solsona MD; Fernández LL; Boquet EM; Andrés JL
    Clin Neuropharmacol; 2012; 35(3):150-1. PubMed ID: 22592512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of AAV-2-mediated aspartoacylase gene transfer in the tremor rat model of Canavan disease.
    McPhee SW; Francis J; Janson CG; Serikawa T; Hyland K; Ong EO; Raghavan SS; Freese A; Leone P
    Brain Res Mol Brain Res; 2005 Apr; 135(1-2):112-21. PubMed ID: 15857674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.